strikes

China’s biopharma market strikes $30b in oncology licensing offers

In 2024, antibody-drug conjugates controlled the licensing project. China’s biopharmaceutical market has actually seen a sharp surge in oncology medication licensing arrangements in 2024, specifically monoclonal antibodies (MABS) and antibody-toxin…

June 6, 2025

Asia Business News (ISSN: 3079-8531) is a leading international business publication dedicated to delivering in-depth analysis, expert insights, and comprehensive coverage of economic trends, corporate developments, and market dynamics across the Asia-Pacific region and beyond. With a commitment to journalistic integrity and analytical rigor, Asia Business News serves as a trusted source of information for business leaders, policymakers, and investors seeking authoritative perspectives on global commerce, finance, and industry advancements.

China’s biopharma market strikes $30b in oncology licensing offers

Samsung to spend $117m in Indian center after labor strikes

Indonesia strikes 5 offers to finish Trump’s tolls

Impressive Mobile First Website Builder

About Company